<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848729</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14564059</org_study_id>
    <nct_id>NCT02848729</nct_id>
  </id_info>
  <brief_title>Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen</brief_title>
  <official_title>A Randomized, 2-Way, Parallel, Single-Blind Pharmacokinetic Study to Evaluate the Interaction Between Intravenous Morphine and Orally or Intravenously Administered Acetaminophen in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Morphine is the opioid used to treat pain after surgery. Acetaminophen (called APAP) can
      reduce the amount of opioids needed for this.

      The problem is that morphine slows down digestion. That can delay pain relief from APAP
      pills. It can even change what the body does to the drug [pharmacokinetics (PK)].

      Some doctors have started using intravenous (IV) APAP with morphine, instead of the pills.

      This study will measure the PK of APAP pills and IV when used with morphine in healthy
      volunteers.

      IV APAP will likely be more effective and cause fewer side effects when used with morphine to
      treat pain after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acetaminophen can significantly reduce the use of opioid analgesics when both are used
      concomitantly for treating moderate to severe pain. The use of IV acetaminophen used
      concomitantly with opioids has increased in practice for postsurgical pain relief over orally
      administered acetaminophen because it provides an immediate peak plasma concentration and is
      believed to provide a faster analgesic effect. Opioids used to treat pain inhibit
      gastrointestinal motility, including delaying gastric emptying. In patients receiving opioids
      the absorption of orally administered acetaminophen may be delayed and could result in
      gastric accumulation of acetaminophen thereby markedly changing the pharmacokinetic profile.
      The opioid-induced inhibition of gastrointestinal motility would not be expected to affect IV
      acetaminophen pharmacokinetics. Thus coadministered IV acetaminophen with opioid would yield
      better outcome in efficacy and reduced risk of side effects comparing with coadministration
      of oral acetaminophen and opioids.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve Over 6 Hours (AUC6) for Acetaminophen</measure>
    <time_frame>hours -6 to 0, 0-6, 6-12, and 12-18 during treatment with each mode of acetaminophen administration</time_frame>
    <description>The area under the plasma drug concentration-time curve (AUC) is an estimate of how much drug remains available for the body to use, within a certain amount of time after the drug is administered. AUC6 is reported for each of the 6-hour dosing periods of acetaminophen before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve Over 18 Hours (AUC18) for Acetaminophen After First Morphine Co-administration</measure>
    <time_frame>hours 0-18 during treatment with each mode of acetaminophen administration</time_frame>
    <description>AUC18 is reported for the 18-hour treatment period after first morphine co-administration, for each route of acetaminophen administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Acetaminophen</measure>
    <time_frame>hours -6 to 0, 0-6, 6-12, and 12-18 during treatment with each mode of acetaminophen administration</time_frame>
    <description>Following the administration of drugs, the plasma concentration generally reaches a single, well-defined peak which is the most drug that is available for the body to use (Cmax). Cmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12), and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of Acetaminophen</measure>
    <time_frame>hours -6 to 0, 0-6, 6-12 and 12-18 during treatment with each mode of acetaminophen administration</time_frame>
    <description>Following the administration of drugs, the time at which the plasma concentration reaches Cmax is called Tmax. Tmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Treatment A: Oral Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an IV infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of intravenous (IV) morphine (0.125 mg/kg) at Hours 0 and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: IV Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Acetaminophen</intervention_name>
    <description>Acetaminophen for oral administration (2 tablets, 500 mg/tablet)</description>
    <arm_group_label>Treatment A: Oral Acetaminophen</arm_group_label>
    <other_name>APAP Oral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Acetaminophen</intervention_name>
    <description>Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)</description>
    <arm_group_label>Treatment B: IV Acetaminophen</arm_group_label>
    <other_name>APAP IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Morphine</intervention_name>
    <description>Morphine for IV administration (0.125 mg/kg)</description>
    <arm_group_label>Treatment A: Oral Acetaminophen</arm_group_label>
    <arm_group_label>Treatment B: IV Acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablets</intervention_name>
    <description>Placebo tablets matching oral acetaminophen</description>
    <arm_group_label>Treatment B: IV Acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline placebo matching IV acetaminophen</description>
    <arm_group_label>Treatment A: Oral Acetaminophen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have a health status of &quot;healthy&quot; assessed by the investigator and
             defined as no clinically significant deviation from normal medical history, physical
             examination, vital signs, and clinical laboratory determinations.

          2. Subject must have a body mass index ≥ 19.0 and ≤ 32.0 kg/m² with a minimum weight of
             110 pounds (50 kg) at Screening.

        Exclusion Criteria:

          1. Subject has a positive test result for human immunodeficiency virus (HIV), hepatitis B
             (surface antigen), or hepatitis C virus antibody at screening.

          2. Subject has a history of any drug allergy, hypersensitivity, or intolerance to
             acetaminophen or morphine/opioids or to any of the excipients in the IV or oral
             formulations used.

          3. Subject has an oxygen saturation of less than 95% while awake at screening and
             check-in.

          4. Subject has a positive test result for drugs of abuse (minimum: opioids, barbiturates,
             cannabinoids, benzodiazepines, cocaine, amphetamine) or alcohol at the screening and
             check-in.

          5. Subject has donated or had significant loss of whole blood (480 mL or more) within 30
             days, or plasma within 14 days prior to dosing.

          6. Subject has any other medical, psychiatric and/or social reason for exclusion as
             determined by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona College of Pharmacy</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEMA Research, Inc.</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Rhode Island College of Pharmacy</name>
      <address>
        <city>Kingston</city>
        <state>Rhode Island</state>
        <zip>02881</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <results_first_submitted>December 6, 2019</results_first_submitted>
  <results_first_submitted_qc>January 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2020</results_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-surgical pain</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Acetaminophen</title>
          <description>Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an intravenous (IV) infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.</description>
        </group>
        <group group_id="P2">
          <title>IV Acetaminophen</title>
          <description>Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Emesis</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants with emesis were removed from the study, with no replacement. Because 7 of 9 females had emesis at the first dose, an amendment was written to exclude females. Therefore, demographics are provided for the per protocol population.</population>
      <group_list>
        <group group_id="B1">
          <title>Oral Acetaminophen</title>
          <description>Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an IV infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.</description>
        </group>
        <group group_id="B2">
          <title>IV Acetaminophen</title>
          <description>Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.1" spread="9.82"/>
                    <measurement group_id="B2" value="32.5" spread="11.25"/>
                    <measurement group_id="B3" value="32.8" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino Ethnicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve Over 6 Hours (AUC6) for Acetaminophen</title>
        <description>The area under the plasma drug concentration-time curve (AUC) is an estimate of how much drug remains available for the body to use, within a certain amount of time after the drug is administered. AUC6 is reported for each of the 6-hour dosing periods of acetaminophen before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration</description>
        <time_frame>hours -6 to 0, 0-6, 6-12, and 12-18 during treatment with each mode of acetaminophen administration</time_frame>
        <population>Per-protocol population, which is defined as the participants who received all study medication, provided all 33 blood samples within required time points and completed the study with no major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>First Dose - Before Morphine Co-administration</title>
            <description>AUC6 for acetaminophen before morphine co-administration (hours -6 to -1)</description>
          </group>
          <group group_id="O2">
            <title>Second Dose - During Morphine Co-administration</title>
            <description>AUC6 for acetaminophen during morphine co-administration (hours 0 to 6)</description>
          </group>
          <group group_id="O3">
            <title>Third Dose - During Morphine Co-administration</title>
            <description>AUC6 for acetaminophen during morphine co-administration (hours 6 to 12)</description>
          </group>
          <group group_id="O4">
            <title>Fourth Dose - After Morphine Co-administration</title>
            <description>AUC6 for acetaminophen after morphine co-administration (hours 12 to 18)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve Over 6 Hours (AUC6) for Acetaminophen</title>
          <description>The area under the plasma drug concentration-time curve (AUC) is an estimate of how much drug remains available for the body to use, within a certain amount of time after the drug is administered. AUC6 is reported for each of the 6-hour dosing periods of acetaminophen before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration</description>
          <population>Per-protocol population, which is defined as the participants who received all study medication, provided all 33 blood samples within required time points and completed the study with no major protocol deviations.</population>
          <units>hour*microgram per milliliter (h*mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment A: Oral Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.00" spread="5.11"/>
                    <measurement group_id="O2" value="28.51" spread="5.96"/>
                    <measurement group_id="O3" value="25.31" spread="11.59"/>
                    <measurement group_id="O4" value="52.38" spread="13.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment B: IV Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.56" spread="3.94"/>
                    <measurement group_id="O2" value="44.37" spread="4.46"/>
                    <measurement group_id="O3" value="43.59" spread="4.21"/>
                    <measurement group_id="O4" value="49.05" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve Over 18 Hours (AUC18) for Acetaminophen After First Morphine Co-administration</title>
        <description>AUC18 is reported for the 18-hour treatment period after first morphine co-administration, for each route of acetaminophen administration</description>
        <time_frame>hours 0-18 during treatment with each mode of acetaminophen administration</time_frame>
        <population>Per-protocol population, which is defined as the participants who received all study medication, provided all 33 blood samples within required time points and completed the study with no major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>After First Dose of Morphine Co-administration</title>
            <description>AUC18 after first dose of morphine co-administration (hours 0-18)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve Over 18 Hours (AUC18) for Acetaminophen After First Morphine Co-administration</title>
          <description>AUC18 is reported for the 18-hour treatment period after first morphine co-administration, for each route of acetaminophen administration</description>
          <population>Per-protocol population, which is defined as the participants who received all study medication, provided all 33 blood samples within required time points and completed the study with no major protocol deviations.</population>
          <units>hour*microgram per milliliter (h*mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment A: Oral Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.50" spread="23.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment B: IV Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.58" spread="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Acetaminophen</title>
        <description>Following the administration of drugs, the plasma concentration generally reaches a single, well-defined peak which is the most drug that is available for the body to use (Cmax). Cmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12), and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.</description>
        <time_frame>hours -6 to 0, 0-6, 6-12, and 12-18 during treatment with each mode of acetaminophen administration</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>First Dose - Before Morphine Co-administration</title>
            <description>Pharmacokinetics of oral acetaminophen before morphine co-administration (hours -6 to -1)</description>
          </group>
          <group group_id="O2">
            <title>Second Dose - During Morphine Co-administration</title>
            <description>Pharmacokinetics of oral acetaminophen during morphine co-administration (hours 0 to 6)</description>
          </group>
          <group group_id="O3">
            <title>Third Dose - During Morphine Co-administration</title>
            <description>Pharmacokinetics of oral acetaminophen during morphine co-administration (hours 6 to 12)</description>
          </group>
          <group group_id="O4">
            <title>Fourth Dose - After Morphine Co-administration</title>
            <description>Pharmacokinetics of oral acetaminophen during morphine co-administration (hours 12 to 18)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Acetaminophen</title>
          <description>Following the administration of drugs, the plasma concentration generally reaches a single, well-defined peak which is the most drug that is available for the body to use (Cmax). Cmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12), and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.</description>
          <population>Per-protocol population</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment A: Oral Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="4.11"/>
                    <measurement group_id="O2" value="7.29" spread="1.82"/>
                    <measurement group_id="O3" value="7.25" spread="3.95"/>
                    <measurement group_id="O4" value="13.5" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment B: IV Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="3.83"/>
                    <measurement group_id="O2" value="17.0" spread="1.48"/>
                    <measurement group_id="O3" value="17.5" spread="1.93"/>
                    <measurement group_id="O4" value="28.5" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Concentration (Tmax) of Acetaminophen</title>
        <description>Following the administration of drugs, the time at which the plasma concentration reaches Cmax is called Tmax. Tmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.</description>
        <time_frame>hours -6 to 0, 0-6, 6-12 and 12-18 during treatment with each mode of acetaminophen administration</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>First Dose - Before Morphine Co-administration</title>
            <description>Pharmacokinetics of oral acetaminophen before morphine co-administration (hours -6 to -1)</description>
          </group>
          <group group_id="O2">
            <title>Second Dose - During Morphine Co-administration</title>
            <description>Pharmacokinetics of oral acetaminophen during morphine co-administration (hours 0 to 6)</description>
          </group>
          <group group_id="O3">
            <title>Third Dose - During Morphine Co-administration</title>
            <description>Pharmacokinetics of oral acetaminophen during morphine co-administration (hours 6 to 12)</description>
          </group>
          <group group_id="O4">
            <title>Fourth Dose - After Morphine Co-administration</title>
            <description>Pharmacokinetics of oral acetaminophen during morphine co-administration (hours 12 to 18)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of Acetaminophen</title>
          <description>Following the administration of drugs, the time at which the plasma concentration reaches Cmax is called Tmax. Tmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.</description>
          <population>Per-protocol population</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oral Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="0.75" upper_limit="2.02"/>
                    <measurement group_id="O2" value="1.64" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O3" value="3.26" lower_limit="0.50" upper_limit="5.85"/>
                    <measurement group_id="O4" value="2.84" lower_limit="1.17" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.25" upper_limit="0.27"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.50" upper_limit="0.50"/>
                    <measurement group_id="O3" value="0.51" lower_limit="0.50" upper_limit="0.57"/>
                    <measurement group_id="O4" value="0.25" lower_limit="0.25" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of the study to the end of study (approximately 2 weeks, including wash-out period)</time_frame>
      <desc>The safety analysis set, defined as all participants who received study drug, was used for the adverse events module.</desc>
      <group_list>
        <group group_id="E1">
          <title>Oral Acetaminophen</title>
          <description>Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an IV infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.</description>
        </group>
        <group group_id="E2">
          <title>IV Acetaminophen</title>
          <description>Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Feeling of relaxation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Infusion site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Mallinckrodt Pharmaceuticals</organization>
      <phone>800-556-3314</phone>
      <email>clinicaltrials@mnk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

